Major Ingredients

Each vial contains Gemcitabine 1 gm as Gemcitabine Hydrochloride USP lyophilized powder for injection.

Major Functionality

Non-Small Cell Lung Cancer: Gemcitabine, in combination with Cisplatin, is indicated as a first-line treatment of patients with locally advanced (inoperable Stage lllA or IIIB) or metastatic (Stage IV) non-small cell lung cancer. Gemcitabine is indicated for the palliative treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.Pancreatic Cancer : Gemcitabine is indicated for the treatment of adult patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine is indicated for patients with 5-FU refractory pancreatic cancer. Bladder Cancer : Gemcitabine is indicated for treatment of advanced bladder cancer (muscle invasive Stage IV tumors with or without metastases) in combination with Cisplatin therapy. Breast Cancer : Gemcitabine in combination with Paclitaxel, is indicated for the treatment of patients with metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline, unless clinically contra-indicated. Ovarian Cancer : Gemcitabine in combination with Carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma who have relapsed following platinum-based therapy.

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.